Human FGFR2 beta (IIIb) Domain Protein
Catalog No: FGFR2-HP007
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human FGFR2 beta (IIIb) Domain Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Pro253-Glu378 (UniProt accession: P21802-3).
Product Details
- Molecular Aliases
- Fibroblast growth factor receptor 2;FGFR-2;KGFR;K-sam;Keratinocyte growth factor receptor;CD332;BEK;KSAM
- Protein Length
- Pro253-Glu378
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 40.5 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 24 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human FGFR2 beta (IIIb) Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human FGFR2 beta (IIIb) Domain is greater than 95% as determined by SEC-HPLC.
Immobilized Human FGFR2 beta (IIIb) Domain, hFc Tag at 1μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-FGFR2 (IIIb) Antibody, hFc Tag with the EC50 30.7ng/ml determined by ELISA.
Background
Four distinct genes encoding closely related FGF receptors, FGF R1 - 4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1 - 3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha isoform, or only IgII and IgIII, referred to as the beta isoform.
References
- Katoh, Masaru. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)[J]. International Journal of Molecular Medicine, 2016.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.